Cell-Free DNA As Peripheral Biomarker of Alzheimer’s Disease DOI Creative Commons
Sachi Khemka, Ujala Sehar, Pulak R. Manna

et al.

Aging and Disease, Journal Year: 2024, Volume and Issue: unknown

Published: Jan. 1, 2024

Alzheimer's disease (AD) and disease-related disorders (ADRD) are progressive neurodegenerative diseases without cure. occurs in 2 forms, early-onset familial AD late-onset sporadic AD. Early-onset is a rare (~1%), autosomal dominant, caused by mutations presenilin-1, presenilin-2, amyloid precursor protein genes the other late-onset, prevalent evolved due to age-associated complex interactions between environmental genetic factors, addition apolipoprotein E4 polymorphism. Cellular senescence, promoting impairment of physical mental functions constituted be main cause aging, primary risk factor for AD, which results loss cognitive function, memory, visual-spatial skills an individual live or act independently. Despite significant progress understanding biology pathophysiology we continue lack definitive early detectable biomarkers and/or drug targets that can used delay development ADRD elderly populations. However, recent developments studies DNA double-strand breaks result release fragmented into bloodstream contribute higher levels cell-free (cf-DNA). This cf-DNA released from various cell types, including normal cells undergoing apoptosis necrosis elevated blood have potential serve as blood-based biomarker detection ADRD. The overall goal our study discuss latest circulating progression Our article summarized status research on both healthy states how these develop also discussed impact lifestyle epigenetic factors involved

Language: Английский

Tumor biomarkers for diagnosis, prognosis and targeted therapy DOI Creative Commons
Yue Zhou, Lei Tao, Jiahao Qiu

et al.

Signal Transduction and Targeted Therapy, Journal Year: 2024, Volume and Issue: 9(1)

Published: May 20, 2024

Abstract Tumor biomarkers, the substances which are produced by tumors or body’s responses to during tumorigenesis and progression, have been demonstrated possess critical encouraging value in screening early diagnosis, prognosis prediction, recurrence detection, therapeutic efficacy monitoring of cancers. Over past decades, continuous progress has made exploring discovering novel, sensitive, specific, accurate tumor significantly promoted personalized medicine improved outcomes cancer patients, especially advances molecular biology technologies developed for detection biomarkers. Herein, we summarize discovery development including history conventional innovative used biomarker classification biomarkers based on tissue origins, application clinical management. In particular, highlight recent advancements biomarker-based anticancer-targeted therapies emerging as breakthroughs promising strategies. We also discuss limitations challenges that need be addressed provide insights perspectives turn into opportunities this field. Collectively, multiple emphasized review may guidance precision medicine, broaden horizons future research directions, expedite patients according their rather than organs origin.

Language: Английский

Citations

179
Aggregation-Induced Emission Luminogen: Role in Biopsy for Precision Medicine DOI Creative Commons
Yanhong Duo, Lei Han, Yaoqiang Yang

et al.

Chemical Reviews, Journal Year: 2024, Volume and Issue: 124(20), P. 11242 - 11347

Published: Oct. 9, 2024

Biopsy, including tissue and liquid biopsy, offers comprehensive real-time physiological pathological information for disease detection, diagnosis, monitoring. Fluorescent probes are frequently selected to obtain adequate on processes in a rapid minimally invasive manner based their advantages biopsy. However, conventional fluorescent have been found show aggregation-caused quenching (ACQ) properties, impeding greater progresses this area. Since the discovery of aggregation-induced emission luminogen (AIEgen) promoted advancements molecular bionanomaterials owing unique high quantum yield (QY) signal-to-noise ratio (SNR),

Language: Английский

Citations

22
Recent Advancements in the Application of Circulating Tumor DNA as Biomarkers for Early Detection of Cancers DOI Creative Commons

Mahima Mishra,

Rubai Ahmed,

Deepak Kumar Das

et al.

ACS Biomaterials Science & Engineering, Journal Year: 2024, Volume and Issue: 10(8), P. 4740 - 4756

Published: July 1, 2024

Early detection of cancer is vital for increasing patient survivability chances. The three major techniques used to diagnose cancers are instrumental examination, tissue biopsy, and tumor biomarker detection. Circulating DNA (ctDNA) has gained much attention in recent years due advantages over traditional technology, such as high sensitivity, specificity, noninvasive nature. Through the mechanism apoptosis, necrosis, circulating exosome release cells, ctDNA can spread throughout circulatory system carry modifications methylations, mutations, gene rearrangements, microsatellite instability. Traditional gene-detection technology struggles achieve real-time, low-cost, portable measurement, whereas electrochemical biosensors offer low cost, specificity alongside portability ctDNA. Therefore, this review focuses on describing advancements biomarkers various types biosensor developments noninvasive, rapid Further review, sensors also discussed regards their selections probes receptors based electrode surface recognition elements.

Language: Английский

Citations

19
LcProt: Proteomics‐based identification of plasma biomarkers for lung cancer multievent, a multicentre study DOI Creative Commons
Hengrui Liang, Runchen Wang, Ran Cheng

et al.

Clinical and Translational Medicine, Journal Year: 2025, Volume and Issue: 15(1)

Published: Jan. 1, 2025

ABSTRACT Background Plasma protein has gained prominence in the non‐invasive predicting of lung cancer. We utilised Zeolite Zotero NaY‐based plasma proteomics to investigate its potential for multiple event predicting, including cancer diagnosis (task #1), lymph node metastasis detection #2) and tumour‒node‒metastasis (TNM) staging #3). Methods A total 4703 proteins were quantified from 241 participants based on a prospective cohort 2757 participants. An additional 46 external 735 used validation. Feature selection was performed using differential expressed analysis, area under curve (AUC) evaluation least absolute shrinkage operator (LASSO) regression. Random forest multitask model construction key proteins. importance interpreted Shapley additive explanations (SHAP) algorithm. Results For task #1, 10 panel showed an AUC .87 (.77‒.97) After integrating clinical factors, significant increase diagnostic accuracy observed with .91 (.85‒.98). #2, nine achieved .88 (.80‒.96), integration .90 (.85‒.97). #3, (.74‒.96) stage I, .92 (.84‒.97) II, (.76‒.96) III .99 (.98‒.99) IV model. Conclusions This study comprehensively profiled proteome biomarker, laying foundation high‐performance blood test events Key points Our developed innovative nanomaterial, NaY, which addressed masking effect improved depth proteome. The performance as preclinical tool validated through both internal cohort. Furthermore, we explored different patterns changes during progression method elucidate roles predictive

Language: Английский

Citations

3
Emerging digital PCR technology in precision medicine DOI
Lexiang Zhang,

Rokshana Parvin,

Qihui Fan

et al.

Biosensors and Bioelectronics, Journal Year: 2022, Volume and Issue: 211, P. 114344 - 114344

Published: May 14, 2022

Language: Английский

Citations

69
Extrachromosomal circular DNA: biogenesis, structure, functions and diseases DOI Creative Commons
Ludi Yang,

Ruobing Jia,

Tongxin Ge

et al.

Signal Transduction and Targeted Therapy, Journal Year: 2022, Volume and Issue: 7(1)

Published: Oct. 2, 2022

Abstract Extrachromosomal circular DNA (eccDNA), ranging in size from tens to millions of base pairs, is independent conventional chromosomes. Recently, eccDNAs have been considered an unanticipated major source somatic rearrangements, contributing genomic remodeling through chimeric circularization and reintegration into the linear genome. In addition, origin eccDNA be associated with essential chromatin-related events, including formation super-enhancers repair machineries. Moreover, our understanding properties functions has continuously greatly expanded. Emerging investigations demonstrate that serve as multifunctional molecules various organisms during diversified biological processes, such epigenetic remodeling, telomere trimming, regulation canonical signaling pathways. Importantly, its special distribution potentiates a measurable biomarker many diseases, especially cancers. The loss homeostasis facilitates tumor initiation, malignant progression, heterogeneous evolution An in-depth provides novel insights for precision cancer treatment. this review, we summarized discovery history eccDNA, discussed biogenesis, characteristics, eccDNA. emphasized role pathogenesis evolution. Therapeutically, potential clinical applications target aberrant multiple diseases.

Language: Английский

Citations

59
Cell-Free DNA Fragmentomics: The Novel Promising Biomarker DOI Open Access
Ting Qi, Min Pan, Huajuan Shi

et al.

International Journal of Molecular Sciences, Journal Year: 2023, Volume and Issue: 24(2), P. 1503 - 1503

Published: Jan. 12, 2023

Cell-free DNA molecules are released into the plasma via apoptotic or necrotic events and active release mechanisms, which carry genetic epigenetic information of its origin tissues. However, cfDNA is mixture various cell fragments, efficient enrichment fragments with diagnostic value remains a great challenge for application in clinical setting. Evidence from recent years shows that fragmentomics' characteristics differ normal diseased individuals without need to distinguish source makes it promising novel biomarker. Moreover, fragmentomics can identify tissue origins by inferring information. Thus, further insights shed light on fragmentation mechanisms during physiological pathological processes diseases enhance our ability take advantage as molecular tool. In this review, we focus fragment potential application, such length, end motifs, jagged ends, preferred coordinates, well nucleosome footprints, open chromatin region, gene expression inferred pattern across genome. Furthermore, summarize methods deducing fragmentomics.

Language: Английский

Citations

44
Analytical device miniaturization for the detection of circulating biomarkers DOI Creative Commons
Auginia Natalia, Li Zhang, Noah R. Sundah

et al.

Nature Reviews Bioengineering, Journal Year: 2023, Volume and Issue: 1(7), P. 481 - 498

Published: March 31, 2023

Diverse (sub)cellular materials are secreted by cells into the systemic circulation at different stages of disease progression. These circulating biomarkers include whole cells, such as tumour subcellular extracellular vesicles and cell-free factors DNA, RNA proteins. The biophysical biomolecular state carry a rich repertoire molecular information that can be captured in form liquid biopsies for detection monitoring. In this Review, we discuss miniaturized platforms allow minimally invasive rapid analysis biomarkers, accounting their differences size, concentration composition. We examine differently scaled devices enrich, measure analyse specific outlining distinct challenges. Finally, highlight emerging opportunities biomarker device integration provide key future milestones clinical translation. Circulating detected analysed to improve diagnosis This Review discusses assay designs including factors.

Language: Английский

Citations

43
Minimally invasive approaches for the early detection of endometrial cancer DOI Creative Commons

Yufei Shen,

Wenqing Yang, Jiachen Liu

et al.

Molecular Cancer, Journal Year: 2023, Volume and Issue: 22(1)

Published: March 17, 2023

Endometrial cancer (EC) is one of the most common gynecologic cancers and its incidence rising globally. Although advanced EC has a poor prognosis; diagnosing at an earlier stage could improve long-term patient outcomes. However, there no consensus on early detection strategies for current diagnostic practices such as transvaginal ultrasound, hysteroscopy endometrial biopsy are invasive, costly low in specificity. Thus, accurate less invasive screening tests that detect women with stages disease needed. Current research revolutionized novel methodologies many aspects. This review aims to comprehensively characterizes minimally techniques can be applied future, fully demonstrate their potential EC.

Language: Английский

Citations

38
The functional and clinical roles of liquid biopsy in patient-derived models DOI Creative Commons
Ziqing Zhu,

Erya Hu,

Hong Shen

et al.

Journal of Hematology & Oncology, Journal Year: 2023, Volume and Issue: 16(1)

Published: April 8, 2023

The liquid biopsy includes the detection of circulating tumor cells (CTCs) and CTC clusters in blood, as well of, cell-free DNA (cfDNA)/circulating (ctDNA) extracellular vesicles (EVs) patient's body fluid. Liquid has important roles translational research. But its clinical utility is still under investigation. Newly emerged patient-derived xenograft (PDX) CTC-derived (CDX) faithfully recapitulate genetic morphological features donor patients' organoid (PDO) can mostly mimic growth, microenvironment response to drugs. In this review, we describe how development these models assisted studies CTCs terms biological behavior exploration, genomic analysis, drug testing, with help latest technology. We then summarize EVs cfDNA/ctDNA PDX PDO early cancer diagnosis, burden monitoring, test molecular profiling. challenges faced future perspectives research related using are also discussed.

Language: Английский

Citations

31